 15. Patient is currently receiving any of the following medications and cannot be discontinued 7 days prior to starting study drug: a. Known strong inducers or inhibitors of CYP3A45, including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges. b. That have a narrow therapeutic window and are predominantly metabolized through CYP3A45. c. Herbal preparationsmedications, dietary supplements. d. Hormone replacement therapy, topical estrogens including any intra-vaginal preparations, megestrol acetate and selective estrogen-receptor modulators e.g. raloxifene 